1,049 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
JNJ Johnson & Johnson $139.96 $375.48B Uptrend
Article Searches
Johnson & Johnson Is Subpoenaed for Talc Safety Information https://www.wsj.com/articles/doj-sec-subpoena-j-j-for-talc-safety-information-11550709442?mod=pls_whats_news_us_business_f Feb 20, 2019 - Johnson & Johnson said it received subpoenas from the Justice Department and the Securities and Exchange Commission seeking documents related to the safety of its baby powder and other talc-containing products.
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B http://www.zacks.com/stock/news/354868/johnson-johnson-jnj-to-acquire-auris-health-for-%2434b?cid=CS-ZC-FT-354868 Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Flip the Script: Drugmakers Blame Middlemen for Price Increases https://www.wsj.com/articles/flip-the-script-drugmakers-blame-middlemen-for-price-hikes-11549364401?mod=pls_whats_news_us_business_f Feb 05, 2019 - Under pressure over rising drug prices, pharmaceutical companies are pushing a new defense: They’re not raising prices to make money or to cover research costs, but rather to pay a cut to middlemen in the supply chain.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate http://www.zacks.com/stock/news/350873/roche-halts-two-late-stage-studies-on-alzheimers-candidate?cid=CS-ZC-FT-350873 Jan 30, 2019 - Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
3 Big Pharmas Expecting a Softer 2019 https://www.fool.com/investing/2019/01/30/3-big-pharmas-expecting-a-softer-2019.aspx?source=iedfolrf0000001 Jan 30, 2019 - Here's why some of the industry's largest players are telling investors not to expect any fireworks this year.
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/350499/biogen-biib-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-350499 Jan 29, 2019 - Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.
3 Stocks Warren Buffett Might Sell Next https://www.fool.com/investing/2019/01/29/3-stocks-warren-buffett-might-sell-next.aspx?source=iedfolrf0000001 Jan 29, 2019 - With nearly four dozen securities in Berkshire Hathaway's portfolio, these may be next on the chopping block.
Top Research Reports for Johnson & Johnson, Boeing & Starbucks http://www.zacks.com/research-daily/209180/top-research-reports-for-johnson-johnson-boeing-starbucks?cid=CS-ZC-FT-209180 Jan 28, 2019 - Top Research Reports for Johnson & Johnson, Boeing & Starbucks
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN http://www.zacks.com/stock/news/350052/drug-biotech-stock-earnings-on-jan-29-pfe-amgn-biib-agn?cid=CS-ZC-FT-350052 Jan 28, 2019 - Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-ZC-FT-349786 Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.

Pages: 123456789101112...105

<<<Page 7>